Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population

A legfontosabb adatok

Ki végzi
Centre Hospitalier Universitaire de Nīmes
Hol
Franciaország2 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
120 fő, tervezett
Kezdés
2025. márc. 10.
Várható befejezés
2027. szept.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • Blood sample
  • Stool sample
  • CSF sample
A regiszteradat frissítve
2025. november 17.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people with narcolepsy type 1 who have not yet been treated for it, and control people without a sleep disorder of the same sex, similar age and similar body weight class.

Életkor
10 Years and older
Nem
All
A betegség stádiuma
Patients: diagnosed with narcolepsy type 1, not yet treated for narcolepsy at the first evaluation, and able to start treatment for follow-up. Controls: no diagnosed sleep disorder causing excessive sleepiness with an Epworth sleepiness scale score greater than 10/24.
Korábbi kezelés
Patients must not have been treated for narcolepsy at the first evaluation. No antibiotics for an infection in the previous 3 months. No immunomodulatory medicine or chemotherapy within 60 days before joining.

A részvétel fő kizáró okai

  • An infection treated with antibiotics in the previous 3 months, or taking antibiotics during the inclusion period
  • A disease of the immune system
  • Immunomodulatory medicine or chemotherapy within 60 days, or planned during the study
  • A long-term digestive disease, weight-loss (bariatric) surgery in the previous year, or taking laxatives or other treatment that strongly affects gut bacteria
  • Living in a medical institution, or under legal protection, guardianship or curatorship

A regiszter feltételei, szó szerint

Mind a 16 feltétel megnézéseKevesebb

Ki vehet részt

  • Patient diagnosed with narcolepsy type 1 (NT1)
  • Patient not treated for narcolepsy during initial evaluation of NT1 patients
  • Patient eligible for treatment for longitudinal monitoring of NT1 patients
  • Patient speaking and understanding French
  • The patient must have given their free and informed consent and signed the consent form or consent has been provided from the holder(s) of parental authority or the legal guardian and the child
  • The patient must be a member or beneficiary of a health insurance plan
  • Absence of diagnosis of sleep disorder responsible for hypersomnolence with an Epworth sleepiness scale score greater than 10/24

Ki nem vehet részt

  • Subject having presented an infectious pathology requiring antibiotic treatment in the previous 3 months
  • Subject having had treatment with an immunomodulatory molecule or chemotherapy within 60 days before inclusion in the research or whose indication is planned for the duration of the research
  • Subject with a chronic digestive pathology or having undergone bariatric surgery in the previous year
  • Subject with a dysimmune pathology
  • Subject on laxative
  • Subject living in a medical institution
  • Subject under legal protection, guardianship or curatorship
  • Subject and/or their legal representative (if a minor patient) unable to express consent
  • Taking antibiotics during the inclusion period, or laxative or any other treatment having a significant impact on the microbiota

Ez a vizsgálat jelenleg itt érhető el: Franciaország.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Narcolepsy type 1 (NT1) is a rare disease characterized by severe drowsiness, cataplexy, hypnagogic hallucinations, sleep paralysis, poor night sleep, and often obesity. NT1 is caused by irreversible loss of orexin (ORX)/hypocretin neurons in the lateral hypothalamus with decreased ORX levels in the cerebrospinal fluid (CSF). Although the underlying process leading to this destruction remains unclear; an autoimmune origin is suspected.

A teljes eredeti leírásKevesebb

The study authors recently compared the bacterial communities of the fecal microbiota of NT1 patients and control subjects. Initial results demonstrated a difference in overall bacterial community structure in NT1 compared to controls, as assessed by beta diversity, even after adjusting for body mass index (BMI). The Shannon biodiversity index was also correlated with the duration of NT1 disease. However, no association was found between the structure of the microbial community and the clinical characteristics of NT1 patients.

In 2022, a second study from the SOMNOBANK cohort on a larger population confirmed these results, showing dysbiosis between NT1 patients and the control population. The altered intestinal microbial diversity supports the important role of the environment in the development and pathogenesis of NT1. Other studies have established a link between dysbiosis, intestinal permeability and inflammation in other neuroimmune pathologies. Currently, no study has focused on these phenomena of bacterial translocation, intestinal permeability and immune activation linked to the microbiota in type 1 narcolepsy patients.

The study hypothesis is that NT1 patients with dysbiosis in their intestinal microbiota also present a bacterial translocation with an intestinal origin, leading to a systemic inflammatory syndrome favoring an autoimmune damage destroying hypocretin neurons in the hypothalamus. The study authors suspect that microbial elements (DNA) involved in the autoimmune process could be detected in the CSF. This bacterial translocation could vary over time depending on: i) the progression of the disease and its management; ii) changing dysbiosis and: iii) the increase in intestinal permeability and inflammation.

A vizsgálat 2 csoportja

  • Patients with untreated NT1

    Kezelés: Blood sample, Stool sample és CSF sample

  • Matched controls

    Controls matched on sex, age (+/- 2 years) and BMI class (BMI \< 25: normal; 25 ≤ BMI ≤ 30: overweight; BMI \> 30: obesity)

    Kezelés: Blood sample és Stool sample

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. november 17.